FN als StartseiteRealtimekurse aktiv
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 23,460 | 23,670 | 12:04 | |
| 23,450 | 23,670 | 12:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
|---|---|---|---|---|
| 10:30 | Takeda Pharmaceutical Company Limited: Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung | 144 | Business Wire | |
| Di | Takeda Presents Long-Term Data From Phase 3 ADVANCE-CIDP 3 Trial Of HYQVIA In CIDP Patients | 289 | AFX News | |
| Di | Takeda shares late-stage results for investigational soticlestat in rare epileptic disorders | 9 | PMLiVE | |
| Mo | Takeda Drug Fails Pivotal Tests in 2 Rare Epilepsies; Path Forward Depends on Regulatory Flexibility | 18 | MedCity News | |
| Mo | Takeda drug for rare types of epilepsy misses goal in late-stage trial | 10 | BioPharma Dive | |
| Mo | Epilepsy fail hands late-stage pipeline blow to Takeda | 10 | pharmaphorum | |
| Mo | Ovid hits record low as developer Takeda says seizure drug fails | 10 | Reuters | |
| Mo | Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect | 7 | FierceBiotech | |
| Mo | What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? | 10 | Benzinga.com | |
| Mo | Former Takeda Pharmaceutical President Kunio Takeda Dies at 84 | 4 | nippon.com | |
| Mo | Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies | 5 | Benzinga.com | |
| Mo | Ovid Therapeutics plummets after Takeda's drug fails in late-stage studies | 10 | Reuters | |
| Mo | Takeda's seizure drug fails to meet main goal in late-stage studies | 4 | Reuters | |
| Mo | Takeda, Ascentage Pharma sign option agreement for olverembatinib | 3 | Pharmaceutical Business Review | |
| Mo | Ovid Therapeutics Inc.: Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat | 724 | GlobeNewswire (Europe) | |
| Mo | TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::PH3 TOPLINE RESULTS - SOTICLESTAT TAK-935 IN PATIENTS WITH DRAVET SYNDROME & LENNOX-GASTAUT SYNDROME | 2 | SGX Company Announcements | |
| Mo | TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer | 3 | SEC Filings | |
| Mo | ASCENTAGE-B Rallies 16%+ as Takeda, JP Buys 7.7% Stake | 5 | AASTOCKS | |
| Fr | Takeda signs option agreement with Ascentage for CML drug | 2 | Pharmaceutical Technology | |
| Fr | Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing | 6 | BioPharma Dive |
Seite:
1 2 3 4 5 Weiter >>
288 Nachrichten in den letzten 12 Monaten
TAKEDA PHARMACEUTICAL CO LTD gehört der Branche Chemie an. Der aktuelle Kurs liegt bei 23,600 Euro und damit +0,21 % im Plus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 1,11 Euro errechnet sich eine Dividendendrendite von +4,70 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
